Skip to main content

Table 3 Univariate and multivariate logistic regression models for minimal symptom expression in the development group

From: Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis

Variables Subgroups Univariate analysis Multivariate analysis**
OR 95% CI P value OR 95% CI P value
Gender Male 1      
  Female 0.5 0.19–1.25 0.146    
Age at onset EOMG 1      
  LOMG 1.2 0.42–3.73 0.744    
  Elderly-onset MG 0.76 0.18–3.90 0.713    
MGFA classification II 1      
  III 1.19 0.44–3.45 0.741    
  IV 0.57 0.09–4.58 0.553    
Thymoma Yes 1      
  No 0.71 0.25–1.86 0.494    
Thymectomy No 1      
  Yes 2.2 0.73–8.23 0.192    
Worsening Yes       
  No 2.36 0.78–8.80 0.155    
Autoimmune disease No 1      
  Yes 0.85 0.22–4.21 0.827    
MMT score  > 26 1      
   ≤ 26 2.36 0.54–9.72 0.229    
Anti-AChR Abs titer, nmol/L  > 9 1      
   ≤ 9 0.49 0.15–1.37 0.197    
Duration, months  > 12 1    1   
   ≤ 12 4.41 1.73–11.90 0.002** 3.45 1.23–10.24 0.021
Pyridostigmine dosage, mg/day  ≤ 240       
   > 240 0.46 0.10–2.50 0.339    
MG-ADL score  > 3 1      
   ≤ 3 2.74 0.69–18.36 0.207    
 Bulbar score  ≤ 1 1      
   > 1 2.01 0.81–5.19 0.136    
 Respiratory function Normal 1      
  Abnormal 1.53 0.56–4.65 0.426    
 Limb score  ≤ 1 1      
   > 1 1.51 0.57–4.31 0.418    
 Ocular score  > 2     1   
   ≤ 2 2.87 1.11–8.15 0.036** 6.00 1.82–24.58 0.006
QMG score  ≤ 13 1    1   
   > 13 2.36 0.78–8.80 0.155 11.95 2.31–95.82 0.008
 Extraocular muscle score  ≥ 1 1      
  0 2.52 0.84–9.39 0.124    
 Bulbar muscle score  ≥ 1 1      
  0 0.51 0.17–1.37 0.198    
 Respiratory muscle score  ≥ 80 1      
  65–79 0.98 0.36–2.79     
  50–64 0.75 0.28–9.48     
   < 50 0.81 0.07–16.83     
 Gross motor score  > 9 1    1   
   ≤ 9 2.67 0.90–7.81 0.072* 10.82 2.22–69.13 0.006
 Axial motor score  > 2 1      
   ≤ 2 1.70 0.33–7.48 0.493    
  1. CI, confidence interval, OR odds ratio, MSE minimal symptom expression, EOMG early-onset myasthenia gravis, LOMG late-onset myasthenia gravis, MG myasthenia gravis, MGFA Myasthenia Gravis Foundation of America, AChR acetylcholine receptor, Abs antibodies, MMT manual muscle test, MG-ADL myasthenia gravis-activity of daily living, QMG quantitative myasthenia gravis
  2. *Statistical significance (α = 0.1)
  3. **Statistical significance (α = 0.05)